2016 Assessment of Cardiotoxicity of Tyrosine Kinase Inhibitors In Patients With Chronic Myelogenous Leukemia

Abstract

CML is a haematopoietic stem cell disease, which characterized by a reciprocal translocation between chromosome 9 and 22, resulting in formation of the Philadelphia chromosome (ph chromosome). Tyrosine kinase inhibitors have proven particularly efficient in the treatment of CML. Nevertheless, MTTS can inhibit major pathways in normal or cancerous cell leading to unexpected off-target side effects, morbidity, reduced drug doses, or even drug cessation. Hypertension is one of the complications of TKIs, treatment with TKIs that target vascular endothelial growth factor (VEGF) is associated with hypertension that can be life-threatening and cause